Skip to main content

Table 3 Comparison between the 19th Nationwide survey and the first cohort

From: Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study

 

19th Nationwide survey n; %

First cohort group n; %

p-value

Odds ratio

95% CI

Total

20,475; 100.0

126; 100

 

(crude)

 

Initial IVIG therapy

17,613; 86.0

101; 80.2

0.06

0.91

0.53–1.57

   

0.38*

1.07*

0.88 – 1.30*

Acute phase CAL

2,446; 11.9

6; 4.8

< 0.01

2.71

1.19– 6.17

Cardiac sequelae

772; 3.8

0; 0

< 0.05

0

NA

Additional IVIG therapy

2,860; 14.0

9; 7.1

0.03

2.08

1.06–4.13

  1. CI: confidence interval; CAL: coronary artery lesions.
  2. NA, unable to be calculated because the number contained “0.”
  3. *Adjusted odds ratio for dosage of initial IVIG therapy in both groups was obtained using the Mantel-Haenstzel method adjusted for various initial dosages of intravenous immunoglobulin (2 g/kg, 1 g/kg, 400 mg/kg, or various dosages of IVIG). Adjusted odds ratio for acute-phase CAL, cardiac sequelae, and additional IVIG therapy were not analyzed because there were no descriptions of dosages of various initial IVIG in the nationwide surveys.